Ethical Issues in the Development of Readiness Cohorts in Alzheimer's Disease Research.
Journal of Prevention of Alzheimer's Disease
MetadataShow full item record
Milne, R., Bunnik, E., Tromp, K., Bemelmans, S., Badger, S., Gove, D., Maman, M., et al. (2017). Ethical Issues in the Development of Readiness Cohorts in Alzheimer's Disease Research.. Journal of Prevention of Alzheimer's Disease, 4 (2), 125-131. https://doi.org/10.14283/jpad.2017.5
There is growing interest in the development of novel approaches to secondary prevention trials in Alzheimer's disease to facilitate screening and recruitment of research participants and to reduce the time and costs associated with clinical trials. Several international research collaborations are setting up research infrastructures that link existing research cohorts, studies or patient registries to establish 'trial-ready' or 'readiness' cohorts. From these cohorts, individuals are recruited into clinical trial platforms. In setting up such research infrastructures, researchers must make ethically challenging design decisions in at least three areas: re-contacting participants in existing research studies, obtaining informed consent for participation in a readiness cohort, and disclosure of Alzheimer's disease-related biomarkers. These ethical considerations have been examined by a dedicated workgroup within the European Prevention of Alzheimer's Dementia (EPAD) project, a trans-European longitudinal cohort and adaptive proof-of-concept clinical trial platform. This paper offers recommendations for the ethical management of re-contact, informed consent and risk disclosure which may be of value to other research collaborations in the process of developing readiness cohorts for prevention trials in Alzheimer's disease and other disease areas.
Alzheimer’s disease, Ethics, consent, disclosure, readiness cohort, recruitment
This work was funded through the Ethical Legal and Social Implications work package of the European Prevention of Alzheimer’s Dementia (EPAD) study EPAD receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. RM was also funded through the UK National Institute of Health Research grant to the Cambridge Biomedical Research Centre.
Cambridge University Hospitals NHS Foundation Trust (CUH) (BRC 2012-2017)
European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA) FP7 Innovative Medicines Initiative (IMI) (115736-2 (EPAD))
Embargo Lift Date
External DOI: https://doi.org/10.14283/jpad.2017.5
This record's URL: https://www.repository.cam.ac.uk/handle/1810/277406